May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Short-Term Functional Results After Intravitreal Bevacizumab (AvastinTM) for Age-Related Macular Degeneration
A. M. Minnella; B. Falsini; A. Scupola; P. Sasso; L. Ziccardi; G. Stifano; L. Montrone; D. Marangoni; A. Mastrocola; E. Balestrazzi
Author Affiliations & Notes
  • A. M. Minnella
    Ophthalmology, Catholic University, Rome, Italy
  • B. Falsini
    Ophthalmology, Catholic University, Rome, Italy
  • A. Scupola
    Ophthalmology, Catholic University, Rome, Italy
  • P. Sasso
    Ophthalmology, Catholic University, Rome, Italy
  • L. Ziccardi
    Ophthalmology, Catholic University, Rome, Italy
  • G. Stifano
    Ophthalmology, Catholic University, Rome, Italy
  • L. Montrone
    Ophthalmology, Catholic University, Rome, Italy
  • D. Marangoni
    Ophthalmology, Catholic University, Rome, Italy
  • A. Mastrocola
    Ophthalmology, Catholic University, Rome, Italy
  • E. Balestrazzi
    Ophthalmology, Catholic University, Rome, Italy
  • Footnotes
    Commercial Relationships  A.M. Minnella, None; B. Falsini, None; A. Scupola, None; P. Sasso, None; L. Ziccardi, None; G. Stifano, None; L. Montrone, None; D. Marangoni, None; A. Mastrocola, None; E. Balestrazzi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2716. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Short-Term Functional Results After Intravitreal Bevacizumab (AvastinTM) for Age-Related Macular Degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      A. M. Minnella, B. Falsini, A. Scupola, P. Sasso, L. Ziccardi, G. Stifano, L. Montrone, D. Marangoni, A. Mastrocola, E. Balestrazzi; Short-Term Functional Results After Intravitreal Bevacizumab (AvastinTM) for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2716. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To assess the short-term effects of intravitreal bevacizumab injection on retinal function by focal electoretinogram (fERG) and microperimetry (MP1).

Methods: : Twenty-one patients with exudative age related-macular degeneration (AMD) were treated with 0.125 mg/ml of intravitreal bevacizumab and evaluated, before and after injection, by best spectacle corrected visual acuity (BSCVA), fERGs to 8 Hz and 41 Hz flicker stimulation (central 18 degrees), MP1 sensitivity (central 10 degrees) and fixation stability. During 1-month follow-up, none of the patients underwent re-injection and the following parameters were considered: BSCVA, fERG 8 Hz 1st and 2nd harmonic response amplitude and 41 Hz 1st harmonic, MP1 sensitivity and 2° and 4° fixation stabillity.

Results: : When compared to baseline values, BSCVA, MP1 sensitivity and fixation stability improved (p < 0.001) at the end of study. No significant changes were observed for any of the FERG parameters. Significant positive correlations (r = 0.56; p < 0.01) were observed between microperimetry parameters and BSCVA at 30 days after injection.

Conclusions: : Results suggest an improvement of central retinal function following intravitreal bevacizumab for AMD.

Keywords: age-related macular degeneration • drug toxicity/drug effects • choroid: neovascularization 
© 2008, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2015 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept